Previous 10 | Next 10 |
BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Oct. 4, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Ja...
Summary BioMarin Pharmaceutical's revenue was $533.8 million in Q2 2022, up 6.4% year-on-year. The company's net income has been growing at a substantial pace in recent quarters, helping to keep BioMarin Pharmaceutical's business profitable. The company's medicines have receiv...
Biotech stocks are stocks of companies that are involved in the research and development of new drugs, medical devices, and other health-related technologies. Biotech investors like these stocks for many reasons, but most importantly because they offer the potential for high growth. The adv...
BioMarin Pharmaceutical ( NASDAQ: BMRN ) on Thursday said it had resubmitted its biologics license application (BLA) to the U.S. FDA for its gene therapy valoctocogene roxaparvovec for the treatment of severe hemophilia A. The FDA had previously rejected the BLA in Aug. ...
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA PR Newswire BLA Includes Substantial Body of Data from Pivotal Phase 3 and Ongoing Phase 1/2 Studies If Approved, Would Be ...
Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Summary Ascendis Pharma is now a commercial-stage company with a full pipeline and a revenue stream. There are multiple upcoming catalysts, including oncology data due by year end, which may validate the breadth of the platform. TransCon PTH has a large commercial opportunity....
BioMarin Pharmaceutical ( NASDAQ: BMRN ) said that an updated Institute for Clinical and Economic Review (ICER) Draft Evidence Report on gene therapy Roctavian for hemophilia A provides substantial cost savings and projected gains in quality adjusted life years . The r...
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report PR Newswire Institute for Clinical and Economic Review (ICER) Base-Ca...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
BioMarin to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Monday, August 5, 2024, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , July 23, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander ...
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...